Eicosanoid

Quinn Karylle Fuentes · 28問 · 2年前

通報

問題一覧

Pain and inflammatory reaction

Prostaglandins.

Arachidonic acid (AA)-derived lipid mediators are called

Eicosanoid.

Eicosa means how many carbon attached?

20 carbon.

What is the suffix of carboxylic acid?

Oic acid.

Why is it called as eicosatetraenoic acid?

Eiocosa- 20 carbon, Tetra- 4, en - double bond and Oic acid - carboxylic acid.

the most common precursor of the eicosanoids, is formed by two pathways

Phospholipase C, Phospholipase A

concert with diglyceride lipase can also produce free arachidonate

Phospholipase C

Mediated production from membrane phospholipids

Phospholipase A

What is the scientific name of arachidonic acid.

5,8,11,14 -Eicosatetranoic acid.

What are the pathways of Arachidonic Acid

Prostaglandin H synthase (COX) pathway, Lipoxygenase pathway (LOX)

In Cox pathway what is the AA intermediate metabolite

PGH2

What is the pathway make use of COX

Thromboxane, Primary prostaglandins.

What are tha primary prostaglandins

PGE, PGF, PGD, PGI2

What are the drug of choice in COX pathway

NSAID.

What is the drug of choice in LOX inhibitor

Zileuton, Leukotriene antagonist.

This medicine is for broninchial asthma

Zilueton.

This medicine used to block leukotriene.

Leukotriene antagonist.

This is located in endothelial cells, kidney, gastrointestinal tract, and many other locations

COX 1

Found in great abundance in connective tissues.

COX 2

expressed at fairly constant levels PGH synthase-1 (COX-1) is expressed constitutively in most cells

COX 1

It is highly inducible by numerous factors associated with inflammation

COX 2

generates prostanoids for “housekeeping” such as gastric epithelial cytoprotection

COX 1

Current theories suggest that the type 2 isoforms is predominantly associated with eicosanoids production in inflammation.

COX 2

The eicosanoids all have short plasma half-lives (typically 0.5-5 minutes). Most catabolism occurs in the lung

Prostaglandin H-Pathway.

Prostaglandins are metabolized by PDGH to 15-keto metabolites ( T/F)

True.

Thromboxane A2 (TXA2) is rapidly hydrated to the less active TXB2. (T/F)

True.

PGI2 is hydrolyzed to 6-keto-PGF. (T/F)

True.

This pathway is of great interest since it is associated with asthma, anaphylactic shock, and cardiovascular disease

lipoxygenase pathway.

What is the primary components of the slow-reacting substance of anaphylaxis (SRS-A)

LTC 4, LTD 4

Vasodilation

PGE2, PGI2

Arteriolar vasodilation and superficial vein constriction

PGF

Vasoconstriction

Thromboxane.

Bronchoconstriction

Thromboxane., PGF2

Bronchodilation

PGE series.

Bronchoconstriction (SRS-A

LTC4 & LTD4

Uterine contraction Causes pain in dysmenorrhea

PGE2, PGF2

Increase blood flow and promote but do not cause, edema

PGE2, PGI2

Produce LeukotrienesFacilitate T-cell proliferation and act as chemoattractants (T/F)

True.

Synthesize PGE2 and TXA2 Causes inflammation in rheumatoid arthritis

Macrophagesm

Chemotaxis of eosinophils and neutrophils

Leukotrienes.

Chemotaxis of eosinophils and neutrophils

PGF2

Cytoprotectant-inhibit acid and pepsinogen secretion in the stomach

PGE2

Inhibit platelet aggregation

PGE2, PGI2

Induce platelet aggregation

TXA2

Stimulate release

5-HPETE

Inhibits release

PGD2, PGI2

Increases body temperature

PGE2

Induces natural sleep

PGD2

Wakefulness

PGE2

Derivatives can lower intraocular pressure

PGE, PGF

(C22:6)

dicosahexaenoic acids

(C20:5)

Eicosapentaenoic

corn, safflower, and sunflower oils

Linoleic acid.

Non selective cox inhibitor = dec prostaglandins synthesis. = PUD (T/F)

True.

Selective inhubition of COX 2 enzyme = dec prostacyclin = INC platelets aggregation (T/F)

True.

What are examples of NSAID DRUGS.

Mefenamic, Ibuprofen, Naproxen, Diclofenax.

What us is they Generic name of Carboprost.

Hemabale.

PGF2 analogue used for therapeutic abortion.

Carboprost (Hemabale)

PGI2 analogue for management of pulmonary

Epoprostenol ( Fiolan)

What us is they Generic name of Epoprostenol

Fiolan.

PGE 1 analogue used for patent ductus arteriosus

Alprostadi( Caverject)

PGE 1 analogue used as cytoprotectant and the adverse effects of this is Abortifacient.

Misoprostol (Cytotec)

What us is they Generic name of Alprostadil.

Caverject

What us is they Generic name of Misoprostol

Cytotect

PGE2 analogue used as in abortion and cervical ripening

Dinoprostone ( Cervidil)

PGF2 a analogue used in management in glaucoma and has a adverse effects of Brown pigmentation in eyelashes

Lantanoprost (Xalant)

What us is they Generic name of Dinoprostone

Cevidil.

What us is they Generic name of lantanoprost

Xalantan

Cell structure.

Cell structure.

28問 • 2年前

Quinn Karylle Fuentes · 29問 · 2年前

Electrolytes and non electrolytes

Electrolytes and non electrolytes

29問 • 2年前

Quinn Karylle Fuentes · 38問 · 2年前

POST LAB (EXP 4)

POST LAB (EXP 4)

38問 • 2年前

Density and specific gravity

Density and specific gravity

Quinn Karylle Fuentes · 18問 · 2年前

FORCES OF ATTRACTION

FORCES OF ATTRACTION

18問 • 2年前

Quinn Karylle Fuentes · 63問 · 2年前

Microbial growth

Microbial growth

63問 • 2年前

Quinn Karylle Fuentes · 61問 · 2年前

Introduction.

Introduction.

61問 • 2年前

Quinn Karylle Fuentes · 97問 · 2年前

Microbial control.

Microbial control.

97問 • 2年前

Quinn Karylle Fuentes · 100問 · 2年前

States of matter

States of matter

100問 • 2年前

Quinn Karylle Fuentes · 86問 · 2年前

Introduction.

Introduction.

86問 • 2年前

Quinn Karylle Fuentes · 77問 · 2年前

Drug development.

Drug development.

77問 • 2年前

Quinn Karylle Fuentes · 9問 · 2年前

CGMP

CGMP

9問 • 2年前

Quinn Karylle Fuentes · 24問 · 2年前

Pharmaceutical ingredients.

Pharmaceutical ingredients.

24問 • 2年前

Quinn Karylle Fuentes · 43問 · 2年前

Powdered & granules

Powdered & granules

43問 • 2年前

Quinn Karylle Fuentes · 24問 · 2年前

Capsule.

Capsule.

24問 • 2年前

Quinn Karylle Fuentes · 23問 · 2年前

Tablets.

Tablets.

23問 • 2年前

Quinn Karylle Fuentes · 3回閲覧 · 66問 · 2年前

Calculatiom of dose

Calculatiom of dose

3回閲覧 • 66問 • 2年前

Quinn Karylle Fuentes · 29問 · 2年前

Postlab 5&6

Postlab 5&6

29問 • 2年前

Quinn Karylle Fuentes · 33問 · 2年前

COLLIGATIVE PROPERTIES.

COLLIGATIVE PROPERTIES.

33問 • 2年前

Quinn Karylle Fuentes · 69問 · 2年前

SEMI SOLID

SEMI SOLID

69問 • 2年前

Quinn Karylle Fuentes · 60問 · 2年前

Basic immunology

Basic immunology

60問 • 2年前

Quinn Karylle Fuentes · 62問 · 2年前

Basic immunology (2)

Basic immunology (2)

62問 • 2年前

Quinn Karylle Fuentes · 44問 · 2年前

Transdermal

Transdermal

44問 • 2年前

Quinn Karylle Fuentes · 43問 · 2年前

Distribution.

Distribution.

43問 • 2年前

Quinn Karylle Fuentes · 65問 · 2年前

Infectious disease.

Infectious disease.

65問 • 2年前

Quinn Karylle Fuentes · 79問 · 2年前

Infectious diseases (2)

Infectious diseases (2)

79問 • 2年前

Gram positive ( Bacteriology)

Gram positive ( Bacteriology)

All topic. ( Compressed.)

All topic. ( Compressed.)

Quinn Karylle Fuentes · 30問 · 2年前

All topic ( Compressed)

All topic ( Compressed)

30問 • 2年前

Quinn Karylle Fuentes · 13問 · 2年前

All topics (compressed)

All topics (compressed)

13問 • 2年前

Quinn Karylle Fuentes · 28問 · 2年前

Exercise 6 ; Isotonic solution.

Exercise 6 ; Isotonic solution.

28問 • 2年前

Quinn Karylle Fuentes · 16問 · 2年前

Exercise 5 : Buffers.

Exercise 5 : Buffers.

16問 • 2年前

Quinn Karylle Fuentes · 26問 · 2年前

Exercise 7 : Factors affecting solubility.

Exercise 7 : Factors affecting solubility.

26問 • 2年前

Quinn Karylle Fuentes · 23問 · 2年前

Experiment 8: Disintegration.

Experiment 8: Disintegration.

23問 • 2年前

Experiment 9 ; Interfacial phenomenon and surface tension.

Experiment 9 ; Interfacial phenomenon and surface tension.

EXP 9 : Aromatic ammonia spirit.

EXP 9 : Aromatic ammonia spirit.

EXP 10-11 : CAMPHOR WATER AND CINNAMON WATER.

EXP 10-11 : CAMPHOR WATER AND CINNAMON WATER.

Quinn Karylle Fuentes · 20問 · 2年前

EXP 12: ACACIA MUCILAGE

EXP 12: ACACIA MUCILAGE

20問 • 2年前

Quinn Karylle Fuentes · 33問 · 2年前

EXP13&14 : Starch and Barrium sulfate.

EXP13&14 : Starch and Barrium sulfate.

33問 • 2年前

Quinn Karylle Fuentes · 37問 · 2年前

EXP 15 : Liquid petroleum emulsion 1.0

EXP 15 : Liquid petroleum emulsion 1.0

37問 • 2年前

Quinn Karylle Fuentes · 23問 · 2年前

EXP 15: Liquid petroleum emulsion 1.1

EXP 15: Liquid petroleum emulsion 1.1

23問 • 2年前

Enterobacteriaceae

Enterobacteriaceae

Quinn Karylle Fuentes · 28問 · 2年前

Enterobacteriaceae.

Enterobacteriaceae.

28問 • 2年前

Quinn Karylle Fuentes · 31問 · 2年前

LIQUID DOSAGE FORM 1.0

LIQUID DOSAGE FORM 1.0

31問 • 2年前

Quinn Karylle Fuentes · 12問 · 2年前

Liquid dosage form

Liquid dosage form

12問 • 2年前

Quinn Karylle Fuentes · 44問 · 2年前

MICROMERITICS 1.0

MICROMERITICS 1.0

44問 • 2年前

Quinn Karylle Fuentes · 22問 · 2年前

EXP 7 : ENDOGENOUS AND EXOGENOUS MICROORGANISMS

EXP 7 : ENDOGENOUS AND EXOGENOUS MICROORGANISMS

22問 • 2年前

Quinn Karylle Fuentes · 40問 · 2年前

EXP 8 : KIRBY-BAUER TECHNIQUE

EXP 8 : KIRBY-BAUER TECHNIQUE

40問 • 2年前

Quinn Karylle Fuentes · 29問 · 2年前

EXP 9: STAPHYLOCOCCI

EXP 9: STAPHYLOCOCCI

29問 • 2年前

Quinn Karylle Fuentes · 41問 · 2年前

Drug incompatibilities.

Drug incompatibilities.

41問 • 2年前

Quinn Karylle Fuentes · 41問 · 2年前

Drug compatibilities.

Drug compatibilities.

41問 • 2年前

BACTERIOLOGY 3

BACTERIOLOGY 3

Quinn Karylle Fuentes · 30問 · 2年前

BACTERIOLOGY 3

BACTERIOLOGY 3

30問 • 2年前

SUSPENSION.

SUSPENSION.

Quinn Karylle Fuentes · 40問 · 2年前

Colloidal.

Colloidal.

40問 • 2年前

Quinn Karylle Fuentes · 38問 · 2年前

BACTERIOLOGY 4 (Rickettsia)

BACTERIOLOGY 4 (Rickettsia)

38問 • 2年前

Quinn Karylle Fuentes · 44問 · 2年前

BACTERIOLOGY.

BACTERIOLOGY.

44問 • 2年前

Quinn Karylle Fuentes · 32問 · 2年前

Emulsion.

Emulsion.

32問 • 2年前

Quinn Karylle Fuentes · 42問 · 2年前

EMULSION

EMULSION

42問 • 2年前

Quinn Karylle Fuentes · 36問 · 2年前

MEDICAL RELATED PROBLEMS.

MEDICAL RELATED PROBLEMS.

36問 • 2年前

Quinn Karylle Fuentes · 33問 · 2年前

MEDICATION RELATED PROBLEMS.

MEDICATION RELATED PROBLEMS.

33問 • 2年前

Quinn Karylle Fuentes · 30問 · 2年前

Mycology.

Mycology.

30問 • 2年前

Mycology 2.0

Mycology 2.0

Quinn Karylle Fuentes · 15問 · 2年前

15問 • 2年前

Quinn Karylle Fuentes · 25問 · 2年前

ppr

ppr

25問 • 2年前

Quinn Karylle Fuentes · 20問 · 2年前

MEDICAL DEVICES.

MEDICAL DEVICES.

20問 • 2年前

Quinn Karylle Fuentes · 86問 · 2年前

Pharmacokinetics. (1.0)

Pharmacokinetics. (1.0)

86問 • 2年前

Quinn Karylle Fuentes · 100問 · 2年前

Pharmacokinetics (1.1)

Pharmacokinetics (1.1)

100問 • 2年前

Quinn Karylle Fuentes · 19問 · 2年前

Pharmacokinetics (1.2)

Pharmacokinetics (1.2)

19問 • 2年前

Quinn Karylle Fuentes · 17問 · 2年前

Introduction.

Introduction.

17問 • 2年前

Quinn Karylle Fuentes · 76問 · 2年前

Introduction of biochemistry

Introduction of biochemistry

76問 • 2年前

Quinn Karylle Fuentes · 56問 · 2年前

Intro medicanal chemistry.

Intro medicanal chemistry.

56問 • 2年前

Quinn Karylle Fuentes · 75問 · 2年前

Carbohydrates

Carbohydrates

75問 • 2年前

Quinn Karylle Fuentes · 31問 · 2年前

Carbohydrates 1.1

Carbohydrates 1.1

31問 • 2年前

Quinn Karylle Fuentes · 56問 · 2年前

Detect and quality variation.

Detect and quality variation.

56問 • 2年前

Quinn Karylle Fuentes · 98問 · 2年前

INTRODUCTION

INTRODUCTION

98問 • 2年前

Quinn Karylle Fuentes · 15問 · 2年前

lab (1-2)

lab (1-2)

15問 • 2年前

Quinn Karylle Fuentes · 14問 · 2年前

lab 1-2

lab 1-2

14問 • 2年前

Pharmaceutical chemistry.

Pharmaceutical chemistry.

Pharmaceutical chemistry 1.1

Pharmaceutical chemistry 1.1

Quinn Karylle Fuentes · 39問 · 2年前

Unit 3.

Unit 3.

39問 • 2年前

Quinn Karylle Fuentes · 70問 · 2年前

Histamin and kinins

Histamin and kinins

70問 • 2年前

PUD.

PUD.

Quinn Karylle Fuentes · 61問 · 2年前

61問 • 2年前

Quinn Karylle Fuentes · 67問 · 2年前

Lipids.

Lipids.

67問 • 2年前

Quinn Karylle Fuentes · 71問 · 2年前

lipids.

lipids.

71問 • 2年前

Quinn Karylle Fuentes · 93問 · 2年前

LAB ✨

LAB ✨

93問 • 2年前

Quinn Karylle Fuentes · 87問 · 2年前

Drug discovery.

Drug discovery.

87問 • 2年前

Quinn Karylle Fuentes · 13問 · 2年前

disease of lipids.

disease of lipids.

13問 • 2年前

Quinn Karylle Fuentes · 57問 · 2年前

Intro (identify structure)

Intro (identify structure)

57問 • 2年前

Quinn Karylle Fuentes · 98問 · 2年前

Carbohydrates

Carbohydrates

98問 • 2年前

Quinn Karylle Fuentes · 96問 · 2年前

Dynamic.

Dynamic.

96問 • 2年前

Quinn Karylle Fuentes · 32問 · 2年前

Unit 1

Unit 1

32問 • 2年前